Business
Ratio Therapeutics Raises $70M to Push Its Targeted Cancer Radiotherapies
The Series C, backed by Eli Lilly and Bristol Myers Squibb, will advance a FAP-targeted radiotherapeutic for sarcoma and expand a pipeline of precision radioligand drugs.